Conjunctivitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Conjunctivitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies https://clinicaltrials.eu/trial/study-of-grass-pollen-extract-and-olive-pollen-extract-for-patients-with-hay-fever-and-asthma-caused-by-grass-and-olive-pollen-allergies/ Wed, 29 Apr 2026 15:09:39 +0000 https://clinicaltrials.eu/trial/study-of-grass-pollen-extract-and-olive-pollen-extract-for-patients-with-hay-fever-and-asthma-caused-by-grass-and-olive-pollen-allergies/ This study is being conducted to evaluate the efficacy and safety of Depigoid DUO in individuals living with allergic rhinoconjunctivitis, which is an allergic reaction affecting the nose and eyes, and potentially asthma, a condition that affects the breathing passages. These symptoms are caused by a sensitivity to grass pollen and olive pollen. The treatment involves subcutaneous injection, which means the medicine is administered via a small needle into the layer of tissue just under the skin. The study compares this treatment to a placebo.

The research aims to determine how well the immunotherapy works compared to a placebo during the periods when pollen levels are highest. Participants will receive a series of injections. During the course of the study, information regarding symptoms such as sneezing, a runny nose, itchy eyes, or breathing difficulties will be recorded. The study also considers the use of other medications, such as antihistamines or intranasal corticoids, which are sprays used to reduce inflammation in the nose.

]]> Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma. https://clinicaltrials.eu/trial/study-of-the-efficacy-and-safety-of-depigmented-polymerized-grass-pollen-extracts-for-patients-with-allergic-rhinitis-and-controlled-asthma/ Wed, 29 Apr 2026 15:09:39 +0000 https://clinicaltrials.eu/trial/study-of-the-efficacy-and-safety-of-depigmented-polymerized-grass-pollen-extracts-for-patients-with-allergic-rhinitis-and-controlled-asthma/ This study aims to evaluate the efficacy and safety of grass pollen immunotherapy for individuals living with allergic rhinoconjunctivitis, which is an allergic reaction affecting the nose and eyes, and may occur with or without controlled asthma. The treatment involves the use of Depigoid Grass-Mix and Depigoid FORTE Grass-Mix, which are suspensions for injection containing extracts from various grass pollens. These extracts have undergone a process to remove color and change their structure to be used for subcutaneous use, meaning they are administered by injection under the skin. A placebo will also be used during the investigation.

The research is conducted in different stages. Initially, a phase involves a double-blind process, where neither the participants nor the researchers know who is receiving the active medication or the placebo. During this stage, participants receive regular injections, and their symptoms and use of medications like antihistamines or intranasal corticoids are monitored. This is followed by an open-label phase, where the treatment details are known to everyone involved. This part of the study looks at how the body responds to different amounts of pollen through a conjunctival provocation test, which is a method used to see how the eyes react when exposed to allergens.

]]> Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis https://clinicaltrials.eu/trial/study-of-sublingual-immunotherapy-with-dermatophagoides-pteronyssinus-and-dermatophagoides-farinae-allergen-mix-for-patients-with-dust-mite-allergic-rhinitis/ Wed, 29 Apr 2026 15:06:55 +0000 https://clinicaltrials.eu/trial/study-of-sublingual-immunotherapy-with-dermatophagoides-pteronyssinus-and-dermatophagoides-farinae-allergen-mix-for-patients-with-dust-mite-allergic-rhinitis/ This study focuses on allergic rhinitis and rhinoconjunctivitis caused by dust mite allergy. The treatment being tested is a mixture of two types of dust mite allergens (Dermatophagoides pteronyssinus and Dermatophagoides farinae) given as a spray under the tongue. The purpose is to find the most effective dose of this allergy treatment that can help patients while remaining safe.

The study will compare different strengths of the allergen mixture (1000, 3000, and 6000 TBU/ml) against a placebo. The medication or placebo will be given as a sublingual spray, which means it is sprayed under the tongue. Participants will receive daily doses for 4 months. To measure how well the treatment works, doctors will perform a nasal provocation test, which involves putting a small amount of allergen in the nose and measuring breathing changes.

During the study, participants will have various tests to check their allergy responses, including skin prick tests and blood tests to measure antibody levels. Doctors will also monitor any side effects and keep track of how often participants need to use other allergy medications. The treatment is designed for people who have allergic reactions to dust mites, which can cause symptoms like sneezing, runny nose, and itchy eyes.

]]> Study on the Safety and Effectiveness of Subcutaneous Immunotherapy with Der p 1, Der p 2, and Der p 23 Allergens for Patients with Allergic Rhinitis or Rhinoconjunctivitis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-subcutaneous-immunotherapy-with-der-p-1-der-p-2-and-der-p-23-allergens-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis/ Wed, 29 Apr 2026 15:04:11 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-subcutaneous-immunotherapy-with-der-p-1-der-p-2-and-der-p-23-allergens-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis/ This clinical trial is focused on studying the effects of a treatment for people with allergic rhinitis or rhinoconjunctivitis, which are conditions that cause symptoms like sneezing, runny nose, and itchy eyes. These conditions are often triggered by allergies to dust mites, specifically the Dermatophagoides species. Some participants may also have allergic asthma, a type of asthma that is influenced by allergies. The treatment being tested is a form of immunotherapy, which involves injecting small amounts of allergens under the skin to help the body build up a tolerance over time. The allergens used in this study are purified forms of Der p 1, Der p 2, and Der p 23, which are proteins found in dust mites.

The purpose of the study is to evaluate the safety and effectiveness of this immunotherapy treatment. Participants will receive injections of the allergens at different doses, and some will receive a placebo. The study will last for a period during which participants will receive 12 maintenance doses. Throughout the study, participants will be monitored to see how their symptoms change and to ensure the treatment is safe. The study aims to find the optimal dose that provides the best balance of benefits and risks.

Participants will be assessed on various factors, including changes in their symptoms, medication use, and quality of life. The study will also look at how well the treatment helps control asthma symptoms for those who have it. Regular check-ups will be conducted to track progress and any side effects. The ultimate goal is to determine if this immunotherapy can effectively reduce symptoms and improve the quality of life for people with these allergic conditions.

]]>